Table 3 Comparison of clinicopathological features between right RCC with GADVR and left RCC with GADVR
Right GADVR (n = 11) | Left GADVR (n = 10) | P | |
|---|---|---|---|
Gender, n (%) | 0.635 | ||
Male | 9 (81.8%) | 7 (70.0%) | |
Female | 2 (18.2%) | 3 (30.0%) | |
Age, y, mean ± SD | 55.09 ± 10.19 | 60.40 ± 6.69 | 0.179 |
Clinical symptoms, n (%) | 1.000 | ||
No | 0 (0%) | 1 (10.0%) | |
Local symptoms | 8 (72.7%) | 8 (80.0%) | |
Systemic symptoms | 1 (9.1%) | 0 (0%) | |
Both | 2 (18.2%) | 1 (10.0%) | |
BMI, kg/m2, mean ± SD | 25.18 ± 2.03 | 24.69 ± 3.32 | 0.687 |
Surgical approach, n (%) | 0.635 | ||
Laparoscope | 2 (18.2%) | 3 (30.0%) | |
Open | 9 (81.8%) | 7 (70.0%) | |
Mayo classification, n (%) | 0.430 | ||
0 | 0 (0%) | 2 (20.0%) | |
1 | 1 (9.1%) | 3 (20.0%) | |
2 | 7 (63.6%) | 12 (50.0%) | |
3 | 3 (27.3%) | 4 (10.0%) | |
IVC segmental resection, n (%) | 0.080 | ||
No | 2 (18.2%) | 6 (60.0%) | |
Yes | 9 (81.8%) | 4 (40.0%) | |
Preoperative serum creatinine, µmol/L, mean ± SD | 109.82 ± 20.89 | 99.40 ± 17.50 | 0.233 |
Serum creatinine one week after operation, µmol/L, median (IQR) | 96.00 (45.00) | 97.50 (49.00) | 0.654 |
Tumor diameter, cm, mean ± SD | 8.70 ± 2.77 | 8.12 ± 2.32 | 0.611 |
Clinical N stage, n (%) | 0.311 | ||
cN0 | 4 (36.4%) | 1 (10.0%) | |
cN1 | 7 (63.6%) | 9 (90.0%) | |
Adrenal metastasis, n (%) | 0.586 | ||
No | 10 (90.9%) | 8 (80.0%) | |
Yes | 1 (9.1%) | 2 (20.0%) | |
Distant metastasis, n (%) | 0.035* | ||
No | 11 (100%) | 6 (60.0%) | |
Yes | 0 (0%) | 4 (40.0%) | |
Bland thrombus, n (%) | 0.030* | ||
No | 2 (18.2%) | 7 (70.0%) | |
Yes | 9 (81.8%) | 3 (30.0%) | |
Sarcomatoid feature, n (%) | 1.000 | ||
No | 9 (81.8%) | 9 (90.0%) | |
Yes | 2 (18.2%) | 1 (10.0%) | |
Perirenal fat infiltration, n (%) | 1.000 | ||
No | 8 (72.7%) | 7 (70.0%) | |
Yes | 3 (27.3%) | 3 (30.0%) | |
Pathology type, n (%) | 0.311 | ||
Clear cell RCC | 10 (90.9%) | 7 (70.0%) | |
Non‐clear cell RCC | 1 (9.1%) | 3 (30.0%) | |
Nuclear grade, n (%) | 1.000 | ||
2 | 4 (36.4%) | 4 (40.0%) | |
3 | 6 (54.5%) | 5 (50.0%) | |
4 | 1 (9.1%) | 1 (10.0%) | |
Lymph node dissection, n (%) | 1.000 | ||
No | 6 (54.5%) | 6 (60.0%) | |
Yes | 5 (45.5%) | 4 (40.0%) | |
ASA grade, n (%) | 0.724 | ||
1 | 1 (9.1%) | 1 (10.0%) | |
2 | 8 (72.7%) | 9 (90.0%) | |
3 | 2 (18.2%) | 0 (0%) | |
Operative time, min, mean ± SD | 338.18 ± 54.97 | 404.30 ± 125.70 | 0.150 |
Surgical blood loss, mL, median (IQR) | 1500.00 (1100.00) | 1000.00 (650.00) | 0.085 |
Postoperative complication, n (%) | 0.395 | ||
No | 4 (36.4%) | 6 (60.0%) | |
Yes | 7 (63.6%) | 4 (40.0%) | |
Severe postoperative complication, n (%) | 1.000 | ||
No | 10 (90.9%) | 9 (90.0%) | |
Yes | 1 (9.1%) | 1 (10.0%) | |
Thrombus adhering to the IVC, n (%) | 0.311 | ||
No | 1 (9.1%) | 3 (30.0%) | |
Yes | 10 (90.9%) | 7 (70.0%) | |